At a glance
ClinicalIndex Comparison RecordN/ACompleted· 38 enrolled
Drug / intervention
FirehawkTM 2.25mmdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.
Shanghai MicroPort Medical (Group) Co., Ltd.·interventional·Posted Feb 23, 2016·Updated Oct 23, 2023
In Brief
A clinical study evaluating FirehawkTM 2.25mm for Coronary Heart Disease. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this study is to evalute the clinical safety and effectiveness of released specification (2.25mm) of FirehawkTM Sirolimus target-eluting coronary stent system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
Primary CompletionDec 2015
First PostedFeb 2016
Study CompletionDec 2020
TodayJul 2026
First PostedFeb 23, 2016
Enrollment StartMay 1, 2014
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.4 years ago
Interventions
FirehawkTM 2.25mmdevice
Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems